A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223

Bayer164 enrolled

Overview

The aim of this non interventional study is to describe the proportion of Belgian mCRPC patients which were treated with 1 to 4 and 5 to 6 Radium-223 injections and the patient characteristics which are potentially associated with this proportion.

Study Type

OBSERVATIONAL

Enrollment

164

Conditions

Prostatic Neoplasms, Castration-Resistant

Interventions

Radium-223 (Xofigo, Bay88-8223)DRUG

Follow the physician's prescription in routine clinical practice.

Eligibility

Sex: MALE

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with a diagnosis of castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases * All consecutive patients who started Radium-223 treatment between 22 December 2014 and 01 June 2017 * Availability of medical records during the observation period (22DEC2013 - 01JUN2018) Exclusion Criteria: * Patients treated with Radium-223 for any reason before 22 December 2014 (for example an interventional trial) * Patients participated in an investigational program with interventions outside of routine clinical practice during the radium-223 treatment period * Patients received other radiopharmaceuticals for the systemic concomitant use for treatment of prostate cancer or for other use during the Radium-223 treatment period

Locations (1)

Many Locations

Multiple Locations, Belgium